PPARγ and RXRγ ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models

Journal of Neurochemistry

Volumn 109, Issue 6, 2009, Pages 1779-1790

  Papi, Alessio ^b   Tatenhorst, Lars ^a   Terwel, Dick ^a   Hermes, Michael ^a   Kummer, Markus P ^a   Orlandi, Marina ^b   Heneka, Michael T ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glioma; Pioglitazone; Proliferator activated receptor; Retinoid; Retinoid X receptor

Indexed keywords

6 HYDROXY 11 O HYDROXYFENANTRENE; CASPASE 3; CYTOCHROME C; GELATINASE A; GELATINASE B; PIOGLITAZONE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BROXURIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IIF COMPOUND; LIGAND; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; RETINOID X RECEPTOR GAMMA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANALYSIS OF VARIANCE; ANIMAL; BRAIN TUMOR; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

MURINAE;

ANALYSIS OF VARIANCE; ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; BROMODEOXYURIDINE; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; LIGANDS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RETINOID X RECEPTOR GAMMA; TETRAZOLIUM SALTS; THIAZOLES; THIAZOLIDINEDIONES; TRANSFECTION; TRETINOIN; TUMOR STEM CELL ASSAY;

EID: 65949117036     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06111.x     Document Type: Article

References (47)

1. Altucci L., Leibowitz M. D., Ogilvie K. M., de Lera A. R. Gronemeyer H. (2007) RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6, 793 810. (Pubitemid 47504871)
2. Asou H., Verbeek W., Williamson E., Elstner E., Kubota T., Kamada N. Koeffler H. P. (1999) Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int. J. Oncol. 15, 1027 1031.
3. Bartolini G., Orlandi M., Ammar K., Magrini E., Ferreri A. M. Rocchi P. (2003) Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. Anticancer Res. 23, 1495 1499. (Pubitemid 36754120)
4. Bartolini G., Ammar K., Mantovani B., Scanabissi F., Ferreri A. M., Rocchi P. Orlandi M. (2004) Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoic acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29. Anticancer Res. 24, 1779 1783. (Pubitemid 38954709)
5. Bartolini G., Orlandi M., Papi A., Ammar K., Guerra F., Ferreri A. M. Rocchi P. (2006) A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells. In Vivo 20, 729 733. (Pubitemid 46061610)
6. Bouterfa H., Picht T., Kess D., Herbold C., Noll E., Black P. M., Roosen K. Tonn J. C. (2000) Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery 46, 419 430. (Pubitemid 30094480)
7. Brandsma D., Stalpers L., Taal W., Sminia P. van den Bent M. J. (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9, 453 461.
8. Castellino R. C. Durden D. L. (2007) Mechanisms of disease: the PI3K-Akt-PTEN signaling node - an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. Neurol. 3, 682 693. (Pubitemid 350238060)
9. Chattopadhyay N., Butters R. R. Brown E. M. (2001) Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. Brain Res. Mol. Brain Res. 87, 100 108. (Pubitemid 32167045)
10. Condorelli F., Salomoni P., Cotteret S., Cesi V., Srinivasula S. M., Alnemri E. S. Calabretta B. (2001) Caspase cleavage enhances the apoptosis-inducing effects of BAD. Mol. Cell. Biol. 21, 3025 3036. (Pubitemid 32298370)
11. Cory S. Adams J. M. (2002) The BCL2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647 656. (Pubitemid 37328916)
12. Crowe D. L. Chandraratna R. A. (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 6, R546 R555.
13. Desjardins A., Rich J. N., Quinn J. A., Vredenburgh J., Gururangan S., Sathornsumetee S., Reardon D. A., Friedman A. H., Bigner D. D. Friedman H. S. (2005) Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 10, 2645 2668. (Pubitemid 40905267)
14. Freemantle S. J., Dragnev K. H. Dmitrovsky E. (2006) The retinoic acid paradox in cancer chemoprevention. J. Natl Cancer Inst. 98, 426 427.
15. Garattini E., Gianni M. Terao M. (2007) Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr. Pharm. Des. 13, 1375 1400. (Pubitemid 46758854)
16. Germain P., Chambon P., Eichele G., Evans R. M., Lazar M. A., Leid M., de Lera A. R., Lotan R., Mangelsdorf D. J. Gronemeyer H. (2006) International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 58, 760 772.
17. Giese A., Bjerkvig R., Berens M. E. Westphal M. (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624 1636. (Pubitemid 46594118)
18. Grommes C., Landreth G. E. Heneka M. T. (2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5, 419 429. (Pubitemid 38878045)
19. Grommes C., Landreth G. E., Sastre M., Beck M., Feinstein D. L., Jacobs A. H., Schlegel U. Heneka M. T. (2006) Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol. Pharmacol. 70, 1524 1533.
20. Hau P., Kunz-Schughart L., Bogdahn U., Baumgart U., Hirschmann B., Weimann E., Muhleisen H., Ruemmele P., Steinbrecher A. Reichle A. (2007) Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. Oncology 73, 21 25.
21. Hellemans K., Kerckhofs K., Hannaert J. C., Martens G., Van Veldhoven P. Pipeleers D. (2007) Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. FEBS J. 274, 6094 6105. (Pubitemid 350135331)
22. Kagechika H. Shudo K. (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J. Med. Chem. 48, 5875 5883. (Pubitemid 41324597)
23. Komatsu K., Nakanishi Y., Nemoto N., Hori T., Sawada T. Kobayashi M. (2004) Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol. 21, 105 112. (Pubitemid 40187984)
24. Kong G., Kim H. T., Wu K., DeNardo D., Hilsenbeck S. G., Xu X. C., Lamph W. W., Bissonnette R., Dannenberg A. J. Brown P. H. (2005) The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 65, 3462 3469. (Pubitemid 40524633)
25. Lopez-Otin C. Matrisian L. M. (2007) Tumour micro environment - opinion - emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800 808.
26. Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., Burger P. C., Jouvet A., Scheithauer B. W. Kleihues P. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97 109.
27. Morosetti R., Servidei T., Mirabella M., Rutella S., Mangiola A., Maira G., Mastrangelo R. Koeffler H. P. (2004) The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int. J. Oncol. 25, 493 502.
28. Murad H., Collet P., Huin-Schohn C. et al. (2006) Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int. J. Oncol. 28, 977 984.
29. Nahoum V., Perez E., Germain P. et al. (2007) Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc. Natl Acad. Sci. USA 104, 17323 17328. (Pubitemid 350219841)
30. Orlandi M., Mantovani B., Ammar K., Avitabile E., Dal Monte P. Bartolini G. (2003) Retinoids and cancer: antitumoral effects of ATRA, 9-cis RA and the new retinoid IIF on the HL-60 leukemic cell line. Med. Princ. Pract. 12, 164 169. (Pubitemid 36667647)
31. Papi A., Bartolini G., Ammar K., Guerra F., Ferreri A. M., Rocchi P. Orlandi M. (2007) Inhibitory effects of retinoic acid and IN on growth, migration and invasiveness in the U87MG human glioblastoma cell line. Oncol. Rep. 18, 1015 1021.
32. Read W. L., Baggstrom M. Q., Fracasso P. M. Govindan R. (2008) A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy 54, 236 241.
33. Redgate E. S., Deutsch M. Boggs S. S. (1991) Time of death of CNS tumor-bearing rats can be reliably predicted by body weight-loss patterns. Lab. Anim. Sci. 41, 269 273.
34. Reed J. C. (1997) Double identity for proteins of the Bcl-2 family. Nature 387, 773 776. (Pubitemid 27270895)
35. Rich J. N., Hans C., Jones B. et al. (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 65, 4051 4058. (Pubitemid 40775641)
36. Shimizu M. Moriwaki H. (2008) Synergistic effects of PPARgamma ligands and retinoids in cancer treatment. PPAR Res. 2008, 181047.
37. Strakova N., Ehrmann J., Bartos J., Malikova J., Dolezel J. Kolar Z. (2005) Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 52, 126 136. (Pubitemid 40503415)
38. Tatenhorst L., Hahnen E. Heneka M. T. (2008) Peroxisome proliferator-activated receptors (PPARs) as potential inducers of antineoplastic effects in CNS tumors. PPAR Res. 2008, 204514.
39. Tiwari M., Kumar A., Sinha R. A., Shrivastava A., Balapure A. K., Sharma R., Bajpai V. K., Mitra K., Babu S. Godbole M. M. (2006) Mechanism of 4-HPR-induced apoptosis in glioma cells: evidences suggesting role of mitochondrial-mediated pathway and endoplasmic reticulum stress. Carcinogenesis 27, 2047 2058. (Pubitemid 44530580)
40. Torp S. H. (2002) Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin. Neuropathol. 21, 252 257. (Pubitemid 35397967)
41. Wen P. Y. Kesari S. (2008) Malignant gliomas in adults. N. Engl. J. Med. 359, 492 507.
42. Wick W., Wagner S., Kerkau S., Dichgans J., Tonn J. C. Weller M. (1998) BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett. 440, 419 424. (Pubitemid 29052326)
43. Yamazaki K., Shimizu M., Okuno M., Matsushima-Nishiwaki R., Kanemura N., Araki H., Tsurumi H., Kojima S., Weinstein I. B. Moriwaki H. (2007) Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells - phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56, 1557 1563. (Pubitemid 350033194)
44. Zander T., Kraus J. A., Grommes C., Schlegel U., Feinstein D., Klockgether T., Landreth G., Koenigsknecht J. Heneka M. T. (2002) Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J. Neurochem. 81, 1052 1060.
45. Zang C., Wachter M., Liu H. et al. (2003) Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J. Neurooncol. 65, 107 118. (Pubitemid 37521308)
46. Ziouzenkova O. Plutzky J. (2008) Retinoid metabolism and nuclear receptor responses: new insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 582, 32 38. (Pubitemid 50019948)
47. Zoli W., Ricotti L., Tesei A., Barzanti F. Amadori D. (2001) In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit. Rev. Oncol. Hematol. 37, 69 82. (Pubitemid 32063319)